Blue­bird whis­tles up a co-de­vel­op­ment/co-pro­mo­tion pact with Cel­gene on bb2121 CAR-T

Blue­bird bio $BLUE has picked up an op­tion to co-pro­mote and co-de­vel­op its close­ly-watched an­ti-BC­MA CAR-T bb2121 for mul­ti­ple myelo­ma pa­tients along­side Cel­gene $CELG. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER